参考文献/References:
[1] Peet MM. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy[J]. Am J Surg ,1948,75(1):48-68.
[2] Fox CS,C oady S,Sorlie PD,et al. Increasing cardiovascular disease burden due to diabetes mellitus - The Framingham Heart Study[J]. Circulation,2007,115(12):1544-1550.
[3] Davies MJ,D’alessio DA,F radkin J,et al. Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetes Care,2018,41(12):2669-2701.
[4] Meng W,E llsworth BA,N irschl AA,et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes[J]. J Med Chem,2008,51(5):1145-1149.
[5] DeFronzo RA,Davidson JA,del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia[J]. Diabetes Obes Metab,2012,14(1):5-14.
[6] Imprialos KP,Sarafidis PA, Karagiannis AI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?[J]. J Hypertens,2015,33(11):2185-2197.
[7] Karg MV,Bosch A,Kannenkeril D,et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content:a randomised controlled trial[J]. Cardiovasc Diabetol,2018,17 (1):5.
[8] Matthews VB,Elliot RH,Rudnicka C,et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2[J]. J Hypertens,2017,35(10):2059-2068.
[9] Han JH,Oh TJ,Lee G,et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE(-/-) mice fed a western diet[J]. Diabetologia,2017,60(2):364-376.
[10] Hayashi T,Fukui T,Nakanishi N,et al. Correction to: dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin[J]. Cardiovasc Diabetol,2017,16(1):149.
[11] Inzucchi SE,Zinman B,Wanner C,et al. SGLT-2 inhibitors and cardiovascular risk:proposed pathways and review of ongoing outcome trials[J]. Diab Vasc Dis Res,2015,12(2):90-100.
[12] Li T,Zhang Z,Kolwicz SC,et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion Injury[J]. Cell Metab,2017,25(2):374-385.
[13] Bertero E,Prates roma L,Ameri P,et al. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis[J]. Cardiovasc Res,2018,114(1):12 -18.
[14] Ndrepepa G. Uric acid and cardiovascular disease[J]. Clin Chim Acta,2018,484:150-163.
[15] Chino Y,Samukawa Y,Sakai S,et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria[J]. Biopharm Drug Dispos,2014,35(7):391-404.
[16] Terami N,Ogawa D,Tachibana H,et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor,dapagliflozin,ameliorates glucose homeostasis and diabetic nephropathy in db/db mice[J]. PLoS One,2014,9(6):e100777.
[17] Bloomgarden Z. The kidney and cardiovascular outcome trials[J]. J Diabetes,2018,10(2):88-89.
[18] Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus[J]. Annu Rev Med,2015,66:255-270.
[19] Saleem F. Dapagliflozin: cardiovascular safety and benefits in type 2 diabetes mellitus[J]. Cureus,2017,9(10):e1751.
[20] 高斯德,李卫萍,李虹伟. 钠-葡萄糖协同转运蛋白抑制剂与心力衰竭的研究进展[J]. 心血管病学进展,2018,39,(5):703-708.
[21] Verma S,Mazer CD,Fitchett D,et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME(?) randomised trial[J]. Diabetologia,2018,61(8):1712-1723.
[22] Fox CS,Golden SH,Anderson C,et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association[J]. Diabetes Care,2015,38(9):1777-1803.
相似文献/References:
[1]王菲 卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
WANG Fei,LU Xinzheng.Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients[J].Advances in Cardiovascular Diseases,2020,(8):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
[2]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白２抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(8):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[3]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
[4]游月婷 汪汉 徐俊波.达格列净在心力衰竭治疗中的研究进展[J].心血管病学进展,2020,(8):830.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.012]
YOU Yueting,WANG Han,XU Junbo.Dapagliflozin in the Treatment of Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):830.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.012]
[5]张欣 郭艺芳.钠-葡萄糖协同转运蛋白2抑制剂相关心血管益处的可能潜在机制[J].心血管病学进展,2020,(9):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]
ZHANG Xin,GUO Yifang.Potential Mechanisms of Sodium-glucose Co-transporter 2 Inhibitor-related Cardiovascular Benefits[J].Advances in Cardiovascular Diseases,2020,(8):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]
[6]和丽丽 左庆娟 张国瑞 郭艺芳.钠-葡萄糖协同转运蛋白2抑制剂使心力衰竭获益的作用机制[J].心血管病学进展,2020,(9):954.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.017]
HE Lili,ZUO Qingjuan,ZHANG Guorui,et al.Mechanism of Benefit of Sodium-glucose Co-transporter 2 Inhibitors in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):954.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.017]
[7].钠-葡萄糖协同转运蛋白2抑制剂获益的研究进展及指南推荐050011；.河北省人民医院老年心血管内科，河北 石家庄 050051）[J].心血管病学进展,2021,(3):252.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.015]
Cardiology Department,The Third Hospital of Shijiazhuang City Affiliated to Hebei Medical University,Shijiazhuang 000,et al.Research Progress and Guideline Recommendations of Cardiovascular Benefits of SGLT-2 Inhibitors[J].Advances in Cardiovascular Diseases,2021,(8):252.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.015]
[8]杨宜恒 郑振中.钠-葡萄糖协同转运蛋白2抑制剂对于未合并2型糖尿病的心力衰竭患者治疗的研究进展[J].心血管病学进展,2021,(12):1093.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.009]
YANG Yiheng,ZHENG Zhenzhong.Treatment of Sodium-Glucose Co-Transporter 2 Inhibitor in Patients with Heart Failure without Type 2 Diabetes[J].Advances in Cardiovascular Diseases,2021,(8):1093.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.009]
[9]张敏 龙开超 唐毅 刘君宇 彭建强.钠-葡萄糖协同转运蛋白2抑制剂使心力衰竭获益机制研究进展[J].心血管病学进展,2021,(12):1096.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.010]
ZHANG Min,LONG Kaichao,TANG Yi,et al.Mechanism of the Benefit of Sodium-Glucose?o-Transporter 2 Inhibitors in Heart Failure[J].Advances in Cardiovascular Diseases,2021,(8):1096.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.010]